OnKure Announces New Date for Upcoming Investor Call
OnKure Therapeutics, Inc. - Class A (OKUR)
Company Research
Source: GlobeNewswire
BOULDER, Colo., Nov. 25, 2024 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ: OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncology, today announced that posters selected for presentation at the 2024 San Antonio Breast Cancer Symposium (SABCS), including the poster presenting the preliminary data from the Company’s first-in-human PIKture-01 trial of OKI-219, will be published to the symposium’s virtual meeting platform for registered attendees on December 10th. OnKure will now hold its investor call to review preliminary data from the PIKture-01 study of OKI-219 on Tuesday, December 10, 2024 at 7:00 a.m. CT (8:00 a.m. ET). The Company had previously announced the investor call would be held on Friday, December 13, 2024. To join the call, please dial 877-407-0789 (domestic), 201-689-8562 (international) and refer to conference ID 13750009. The call may also be accessed via webcast (click here) or from the Events
Show less
Read more
Impact Snapshot
Event Time:
OKUR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OKUR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OKUR alerts
High impacting OnKure Therapeutics, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
OKUR
News
- OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219 [Yahoo! Finance]Yahoo! Finance
- OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219GlobeNewswire
- OnKure Therapeutics (NASDAQ: OKUR) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.MarketBeat
- OnKure Therapeutics (NASDAQ: OKUR) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $33.00 price target on the stock.MarketBeat
- OnKure Announces New Date for Upcoming Investor Call [Yahoo! Finance]Yahoo! Finance
OKUR
Sec Filings
- 12/10/24 - Form 424B3
- 12/10/24 - Form 8-K
- 12/9/24 - Form S-8
- OKUR's page on the SEC website